Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Does BPH Treatment Protect Against Cancer Deaths?

Use of 5-ARIs and risk of prostate cancer mortality

Publish date:: April 21, 2015

In men with a new diagnosis of prostate cancer, 5a-reductase inhibitors (5-ARIs) are not associated with an increased risk of prostate cancer specific or all-cause mortality, a retrospective cohort study of 13,893 men reports.

Researchers estimated hazard ratios (HR) for prostate cancer-specific and all-cause mortality associated with prediagnostic use of 5-ARIs and found an overall crude incidence rate of 3.86 deaths per 100 person years. When stratified by use and non-use of 5-ARIs, the crude incidence rates per 100 patient years are as follows:

	use	non-use	aHR
Prostate cancer-specific mortality	3.76	3.87	0.86
All-cause mortality	8.42	7.93	0.87

Citation: Azoulay L, Eberg M, Benayoun S, Pollak M. 5a-reductace inhibitors and the risk of cancer-related mortality in men with prostate cancer. JAMA Oncol. 2015; doi: 10.1001/jamaoncol.2015.0387

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,